Table of Contents  

Telbivudine – from the discovery of its antiviral activity to a marketed drug (Tyzeka®, Sebivo®) for the treatment of chronic hepatitis B

Gilles Gosselin
Published in : HAMDAN MEDICAL JOURNAL ; Vol 7, No 4 (2014): Volume 7 Supplement 1
DOI : 10.7707/hmj.401

Abstract


A unique series of simple synthetic L -enantiomer nucleosides had been shown by our former laboratories to inhibit hepatitis B virus (HBV) replication. Among them, β -L-2 -deoxythymidine (LdT) or telbivudine (Sebivo®, Novartis Pharmaceuticals, Basel, Switzerland) had the most potent, selective and specific activity against HBV replication, and was selected as an attractive clinical development candidate for the treatment of chronic HBV infection, a worldwide and significant cause of liver-related morbidity and mortality.



View article in  :   PDF     HTML    



Add comment 





Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA